Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Determining a healthy reference range and factors potentially influencing PRO-C3 - A biomarker of liver fibrosis

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Comprehensive lipidomics reveals phenotypic differences in hepatic lipid turnover in ALD and NAFLD during alcohol intoxication

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Hepatic microbiome in healthy lean and obese humans

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Level of MFAP4 in ascites independently predicts 1-year transplant-free survival in patients with cirrhosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Overlapping Mechanisms

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

Background & Aims: Progressive fibrosis has been identified as the major predictor of mortality in patients with non-alcoholic fatty liver disease (NAFLD). Several biomarkers are currently being evaluated for their ability to substitute the liver biopsy as the reference standard. Recent clinical studies in NAFLD/NASH patients support the utility of PRO-C3, a marker of type III collagen formation, as a marker for the degree of fibrosis, disease activity, and effect of treatment. Here we establish the healthy reference range, optimal sample handling conditions for both short- and long-term serum storage, and robustness for the PRO-C3 assay.

Methods: PRO-C3 was measured in 269 healthy volunteers and in 222 NAFLD patients. Robustness of the PRO-C3 assay was measured according to Clinical and Laboratory Standards Institute standards and included validation of interference, precision, and reagent stability, whilst sample stability was defined for storage at different temperatures and for 3 freeze-thaw cycles. Fibrosis scoring was based on histological assessments and used as a reference for the diagnostic ability of PRO-C3 to discriminate between patients with different levels of fibrosis.

Results: Robustness of the PRO-C3 analysis validated by interference, precision, and reagent stability was found to be within the predefined acceptance criteria. The healthy reference range was determined to be 6.1-14.7 ng/ml. Levels of PRO-C3 were not affected by sex, age, BMI, or ethnicity. Levels of PRO-C3 were able to identify patients with clinically significant fibrosis and advanced fibrosis (AUC = 0.83 (95% CI [0.77-0.88], p <0.0001), and AUC = 0.79 (95% CI [0.73-0.85], p <0.0001), respectively).

Conclusions: The assay proved to be robust and sample stability was found to comply with hospital sample handling requirements. PRO-C3 measured in samples from patients with NAFLD/NASH was diagnostic for significant and advanced liver fibrosis.

Lay summary: We showed that PRO-C3 levels were stable under conditions conforming with hospital sample-handling requirements. We determined a healthy reference range and showed that PRO-C3 levels were not associated with sex, age, BMI, or ethnicity. Finally, we provide further evidence of an association of PRO-C3 with increasing liver fibrosis.

Original languageEnglish
Article number100317
JournalJHEP reports : innovation in hepatology
Volume3
Issue number4
ISSN2589-5559
DOIs
Publication statusPublished - Aug 2021

    Research areas

  • Biomarkers, Biopsy, Body mass index, Collagen type III, Ethnic groups, Fibrosis, Healthy volunteers, Hospitals, Humans, Non-alcoholic fatty liver disease, Reference standards, Reference values

ID: 67446636